Skip to content Skip to footer
Subscribe Now
Daiichi Sankyo
NEWS

Daiichi Sankyo Reports First Patient Dosing in P-III (DESTINY-Endometrial01) Study Evaluating ENHERTU

Shots :Daiichi reported the first patient dosing in a P-III (DESTINY-Endometrial01) study evaluating ENHERTU (trastuzumab deruxtecan) + rilvegostomig or pembrolizumab vs Pt. chemotx. (carboplatin and paclitaxel) + pembrolizumab as 1L therapy, in HER2-expressing (IHC 3+/2+), pMMR advanced or recurrent endometrial cancer ptsThe study is assessing the efficacy and safety of ENHERTU (5.4 mg/kg)…
June 10, 2025

Read more

TOP 20

Top 20 Diagnostics Companies of 2025 

Top 20 Diagnostics Companies of 2025 Shots: Driven by continuous innovation and enhanced precision, the diagnostic industry is advancing rapidly, transforming the way healthcare is delivered In 2025, the global diagnostic testing market is valued at approximately $207.96B in 2025 and is projected to grow to around $272.9B by 2034, reflecting a CAGR of 3%.…
May 29, 2025

Read more

Top 20 Medical device companies of 2025
TOP 20

Top 20 Medical Device Companies of 2025

Shots: Driven by continuous innovation, the MedTech sector is evolving rapidly to enhance preventive, diagnostic, and therapeutic capabilities in healthcareIn 2023, the global MedTech market was valued at $668.2B and is projected to reach $989.1B by 2033, growing at a CAGR of approximately 4%. Medtronic led the industry with a revenue of $33.12B, followed…
May 22, 2025

Read more

Ramsoft & Therapixel
NEWS

RamSoft and Therapixel Form a Commercial Partnership For an Integrated AI Breast Imaging Solution

Shots:RamSoft Inc. and Therapixel have entered into a commercial partnership to integrate Therapixel’s MammoScreen AI-powered breast imaging software into RamSoft’s PowerServer and OmegaAI platformsThis collaboration integrates Therapixel's MammoScreen, breast imaging AI, directly into RamSoft's platformsRecent studies showed that MammoScreen improves radiologist performance with 8% higher sensitivity, 2% higher specificity, and 24% faster…
May 21, 2025

Read more

Kalivir Immunotherapeutics
NEWS

KaliVir Immunotherapeutics Reports Completion of First Cohort of P-I/Ib (STEALTH-001) Study in Advanced Solid Tumors

Shots:KaliVir Immunotherapeuticsreported completion of the first cohort in P-I/Ib (STEALTH-001) study evaluating VET3-TGI as a monotx. and in combination with a checkpoint inhibitor in advanced, unresectable, or metastatic solid tumor pts. The Data Safety Committee reviewed initial safety data and approved the progression of VET3-TGI to the next IT and IV dosing cohortsVET3-TGI is an…
May 21, 2025

Read more

Viridian
NEWS

Viridian Therapeutics Releases the Long-Term Durability Data Evaluating Veligrotug in P-III (THRIVE) Study in Active TED 

Shots:Viridian reported positive long-term durability data from the P-III (THRIVE) study evaluating 5 infusions of veligrotug (veli) or PBO (Q3W), with primary topline analysis at 15wks and follow-up to 52wks, in active thyroid eye disease (TED) pts. (N=30)Study demonstrated that 70% (21/30) were proptosis responders at 15wks. and maintained at least a 2…
May 21, 2025

Read more

Know Your Investor: Alexandria Venture (May’25 Edition)
INSIGHTS+

Know Your Investor: Alexandria Venture (May’25 Edition)

Shots:    Welcome to the 2025 edition of Know Your Investor, spotlighting leading venture capital firms driving innovation in healthcare. This edition features Alexandria Venture Investments, a firm committed to supporting disruptive life science companies that aim to improve human health. In 2024, the firm invested approximately $2.7B across six public and private funding rounds, adding…
May 15, 2025

Read more

Top 20 Biopharma Deal Termination 2024
TOP 20

Top 20 Biopharma Deal Terminations of 2024

Shots: In the Biopharma industry, navigating M&A and licensing deals is challenging due to strict antitrust laws and shifting regulations. When these pressures create significant risks, nullifying or restructuring existing agreements can be the most rational and strategic response In 2024, the termination of the $4.45B deal between Adaptimmune and Genentech became a major talking…
May 14, 2025

Read more

Load more